DRUG REACTIONS AND INTERACTIONS

First reports of adverse drug reactions

© Springer International Publishing AG 2017

Table 1 contains an overview of first published case reports of adverse drug reactions identified in the international literature in recent weeks by *Adis Insight*. As part of its drug alerting service, *Adis Insight* provides summaries of recent

adverse drug reactions sourced from journals, scientific meetings, media releases, regulatory agency websites, and bulletins from the National Centres that participate in the WHO International Drug Monitoring Programme.

Drug and adverse reaction	References
Clozapine: DRESS syndrome (serious)	Hassine H, Ouali U, Ouertani A, et al. Clozapine-induced DRESS syndrome with multiple and rare organ involvement. Asian J Psychiatr. 2017;28:146–7. doi:10.1016/j.ajp.2017.04.013
Dantrolene: slurred speech	Low SA, Robbins W, Tawfik VL. Complex management of a patient with refractory primary erythromelalgia lacking a <i>SCN9A</i> mutation. J Pain Res. 2017;10:973–7. doi:10.2147/JPR.S129661
Nivolumab: cryoglobulinaemia (serious)	Pellegrino B, Musolino A, Tiseo M. Anti-PD-1-related cryoglobulinemia during treatment with nivolumab in NSCLC patient. Ann Oncol. 2017;28(6):1405–6. doi:10.1093/annonc/mdx126
Phenobarbital: vasculitis (serious)	Fathallah N, Ladhari C, Slim R, et al. Vasculitis induced by phenobarbital with cross-reactivity to carbamazepine. Therapie. 2017;72(3):387–9. doi:10.1016/j.therap. 2016.07.006
Polylactic acid: late-onset methicillin-resistant Staphylococcus aureus infection (serious)	Choi M, Cheon JS, Choi WY, et al. Late-onset methicillin-resistant <i>staphylococcus aureus</i> infection after facial poly-L-lactic acid injection. Arch Plast Surg. 2017;44(3):248–9. doi:10.5999/aps.2017.44.3.248
Qingdai compound: ischaemic bowel disease and stenosis of the sigmoid colon (serious)	Zhang Z-M, Lin X-C, Ma L, et al. Ischemic or toxic injury: a challenging diagnosis and treatment of drug-induced stenosis of the sigmoid colon. World J Gastroenterol. 2017;23(21):3934–44. doi:10.3748/wjg.v23.i21.3934
Ticagrelor: Sweet's syndrome (serious)	Ikram S, Veerappan Kandasamy V. Ticagrelor-induced Sweet syndrome: an unusual dermatologic complication after percutaneous coronary intervention. Cardiovasc Interv Ther. 2017;32(3):244–6. doi:10.1007/s12928-016-0398-9

An event is serious (US FDA MedWatch definition) when the patient outcome is death, life threatening, hospitalization, disability, congenital anomaly or requires intervention to prevent permanent impairment or damage

DRESS drug reaction with eosinophilia and systemic symptoms